MarketStudyReport.com adds “Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021” new report to its research database. The report spread across 103 pages with table and figures in it.
Spiramycin is a macrolide antibiotic and antiparasitic It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy.
Spiramycin has been used in Europe since the year 2000 under the trade name “Rovamycine”, produced by Rhone-Poulenc Rorer and Famar Lyon, France and Eczacibasi Ilae, Turkey. It also goes under the name Rovamycine in Canada (distributed by OdanLaboratories), where it is mostly marketed to dentists for mouth infections.
Browse full table of contents and data tables @ https://www.marketstudyreport.com/reports/global-spiramycin-base-spiramycin-cas-8025-81-8-market-outlook-2016-2021/
Spiramycin is a 16-membered ring macrolide. It was discovered in 1952 as a product of Streptomyces ambofaciens. As a preparation for oral administration it has been used since 1955, in 1987 also the parenteral form was introduced into practice. The antibiotic action involves inhibition of protein synthesis in the bacterial cell during translocation. Resistance to spiramycin can develop by several mechanisms and its prevalence is to a considerable extent proportional to the frequency of prescription in a given area. The antibacterial spectrum comprises Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium species. Enterobacteria, pseudomonads and pathogenic moulds are resistant. Its action is mainly bacteriostatic, on highly sensitive strains it exerts a bactericide action. As compared with erythromycin, it is in vitro weight for weight 5 to 20 less effective, an equipotential therapeutic dose is, however, only double. This difference between the effectiveness in vitro and in vivo is explained above all by the great affinity of spiramycin to tissues where it achieves concentrations many times higher than serum levels. An important part is played also by the slow release of the antibiotic from the tissue compartment, the marked action on microbes in sub-inhibition concentrations and the relatively long persisting post-antibiotic effect. Its great advantage is the exceptionally favourable tolerance-gastrointestinal and general. It is available for parenteral and oral administration.
Global Spiramycin Base (Spiramycin) (CAS 8025-81-8) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Spiramycin Base (Spiramycin) (CAS 8025-81-8) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Spiramycin Base (Spiramycin) (CAS 8025-81-8) market are Sanofi-Aventis (France), CLL Pharma (Italy), TOPFOND (China), Fortune Pharmaceutical (China), among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Spiramycin Base (Spiramycin) (CAS 8025-81-8) industry has been provided.
To receive personalized assistance, write to us @ firstname.lastname@example.org with the report title in the subject line along with your questions or call us at +1 866-764-2150